Supporting efficacy and scaling with a next-generation T cell AOF formulation medium
Sponsor
The complex manufacturing process of immune-based therapies consists of many steps, including T cell isolation, activation, genetic modification, and expansion. Precise control over the composition and source of components used in cell culture media is critical for each of these steps, which highlights a need for an enhanced formulation that can support all parts of the process. The medium should also help maintain less differentiated naive state since this subset population displays an enhanced functionality and self-renewal capacity in both diseased and non-diseased donors. Therefore, a cell culture medium that supports expansion of T cells with early memory phenotype could improve the clinical outcome of emerging immunotherapies.
This webinar will highlight a novel, next-generation medium with an animal component-free formulation developed to help increase therapeutic potential and to support the cell therapy industry’s need for consistent, reproducible, and automated T cell manufacturing.
- How to support robust expansion of gene-edited early phenotype T cells
- How to optimize expansion of healthy and disease state donor cells
- Enhancing scalability and performance across different culture vessels
- Maintaining cellular functionality throughout expansion
SPEAKERS
You might also like
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies
Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency
Development of a non-viral gene delivery platform for CAR-T manufacturing
Navigating cold chain complexity with innovative solutions
